Teva Pharmaceutical Industries Limited.. (TEVA) Stock AnalysisTEVAStock AnalysisTeva Pharmaceutical Industries Limited..

Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Teva Pharmaceuticals is currently a hold. The stock has seen a significant one-year change of +94.35%, indicating strong past performance. However, the recent RSI of 41.144 suggests it may be approaching oversold territory, and insider selling has increased by 764.83%, which raises concerns about future performance. The forward P/E ratio of 18.2815 indicates reasonable valuation, but mixed earnings results and a recent drop of 2.41% over the last five days suggest caution. Overall, while there are positive catalysts such as analyst upgrades, the risks associated with insider selling and recent earnings performance warrant a hold position for now.

26 analysts cover TEVA: 4 rate it Buy, 17 Hold and 5 Sell. The average price target is 35.71.